Monday, February 26, 2024
ad
HomeNewsAstraZeneca and Absci Will Work Together to Develop a Cancer Drug

AstraZeneca and Absci Will Work Together to Develop a Cancer Drug

Their aim is to leverage Absci’s technology and AstraZeneca’s oncology expertise to expedite the discovery of a drug that can treat cancer.

AstraZeneca has entered a deal potentially worth $247 million with AI biologics company Absci to develop a cancer treatment

Absci Corporation, known for its AI-based antibody discovery, is teaming up with AstraZeneca, a global biopharmaceutical company. They aim to leverage Absci’s technology and AstraZeneca’s oncology expertise to expedite the discovery of a drug that can treat cancer. 

Absci’s Integrated drug creation platform utilizes generative AI and scalable wet-lab technologies. It generates exclusive data by assessing millions of protein-protein interactions. This data serves to train Absci’s unique AI models and subsequently validate antibodies designed through AI models. 

Read More: Mount Sinai Developed the HistoAge Model, an Algorithm that can Predict Age at Death

Puja Sapra, Ph.D., Senior Vice President of Biologics Engineering & Oncology Targeted Delivery at AstraZeneca, expressed enthusiasm about the collaboration, citing it as an exciting chance to employ Absci’s de novo AI antibody creation platform for developing a potential new antibody therapy in oncology. 

The agreement comprises initial fees, research funding, milestone payments, and royalties from product sales.

Subscribe to our newsletter

Subscribe and never miss out on such trending AI-related articles.

We will never sell your data

Join our WhatsApp Channel and Discord Server to be a part of an engaging community.

Boudhayan Ghosh
Boudhayan Ghosh
I am a Journalism and Communication graduate, currently working with Analytics Drift as an Associate Technology Journalist. My other hobbies include consuming art and watching football.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular